Prelude

Facility access is getting harder. Study timelines are extending. IACUC expectations are shifting. If you're in animal health R&D, you already know this. What's harder to find is someone willing to talk about it openly. Ernst Heinen is. Next Tuesday, May 19, at 10 AM CT. Live conversation + Q&A. Reserve your seat here: https://lnkd.in/gKP-cXwk #AnimalHealth #AnimalHealthRnD

Big news: Three weeks from today... We're sitting down with Ernst Heinen, DVM, PhD, VP of Clinical Sciences at Elanco, for the next Animal Health Insights Town Hall. Ernst has spent 35 years in animal health R&D and has been studying the impact of animal rights activism and lobbying on clinical development from inside one of the Big 5. Very few people in this industry have that vantage point. This is a rare chance to hear directly from someone operating at that level about what's actually changing: facility access, study timelines, regulatory direction, and what clinical teams should be doing about it now. Monday, May 19. 10 AM CT. Save your spot: https://lnkd.in/gzmUTQBT #AnimalHealth #AnimalHealthRnD

"If you can build confidence with stubborn people like me, you've got it made." That's from a livestock R&D leader describing what it takes to move his team from paper to digital. Most stories about digital transformation in animal health R&D blame the technology. The technology is almost always the easy part. The hard part is human. Across deployments with 8 of the top 10 animal health pharma companies and all 3 top pet nutrition brands, we've seen the same three resistance patterns in almost every successful adoption. None of them appear in the standard change management playbook, because most of that playbook was built for human pharma. Uncover these three patterns and what sets the breakthrough teams apart: https://lnkd.in/d8U-H6iZ #AnimalHealthRnD #ClinicalResearch #ChangeManagement

Most animal health research published by universities disappears after publication. The science is real. The commercial potential goes unexplored. Joseph Harvey, Head of Animal Health at S&P Global, thinks vet schools could be generating the next wave of startups, not just training veterinarians. But the connection between academia and commercialization is still underdeveloped. Watch the clip, then catch the full replay here: https://lnkd.in/gb996QSi #AnimalHealth #AnimalHealthRnD #VeterinaryResearch

Most animal health startups get acquired before they ever prove they can stand on their own. The Big 5 have the regulatory pathways, the sales forces, the distribution networks. Startups bring the innovation. That pattern seems locked in. But what if it's starting to change? Joseph Harvey has tracked more of these deals than anyone I know. He's Head of Animal Health at S&P Global, 14 years deep in M&A, deal flow, and startup scouting. Next Tuesday we're getting into it. Which categories have real traction. Where the money is flowing. And the question we keep coming back to: can any new entrant break through the Big 5 gravity? Tuesday, April 21 | 10 AM CT. Register now: https://lnkd.in/gWiq86mi #AnimalHealth #VeterinaryResearch

$1.2B in vet tech funding last year. Over 1,100 startups globally. But most of them get acquired before they ever prove they can stand alone. So where does that leave the mid-size animal health companies watching from the sidelines? On April 21, Joseph Harvey, Head of Animal Health at S&P Global, joins Prelude CEO Tommy Buchanan Jackson to break down which startup categories have real traction, how the Big 5 are responding, and what companies at every level should be paying attention to. Joseph has spent 14 years tracking deal flow, profiling startups, and interviewing both incumbent executives and early-stage founders. He sees the full picture. Register for the live session: https://lnkd.in/gggaq37A Can't make it live? Register anyway and we'll send you the recording afterward. #AnimalHealth #AnimalHealthRnD #VeterinaryResearch

The Prelude team is heading to the Animal AgTech Innovation Summit in Fort Worth, April 8-9. 500+ senior leaders from animal health, feed, nutrition, and livestock technology. Roundtables on AI in animal health, the data gap in livestock R&D, and precision nutrition. Boehringer Ingelheim, Merck Animal Health, dsm-firmenich, Elanco, and ADM are all on the program. If you care about how livestock R&D data actually gets collected, managed, and used, this is the room. Our CEO Tommy Buchanan Jackson, VP of Sales Ryan Ohls, and VP of Product Anita Iyer will be on-site both days. If you're attending and want to connect, reach out. #AnimalAgTech #AnimalHealth #LivestockInnovation

60% improvement in the placebo group. That's the number Dr. Marie-Paul Lachaud shared from a cognitive dysfunction study in dogs. The active group? 72%. The drug worked. But imagine walking into a regulatory meeting with a 12-point delta when your placebo group improved that much on its own. Marie-Paul has 35+ years in veterinary clinical development. She co-founded one of the first veterinary CROs in Europe. She's seen this across species, across continents, across therapeutic areas. Her take: in companion animals, the placebo effect may actually be stronger than in human medicine. The dog-owner bond creates a three-way dynamic (patient, owner, practitioner) where the animal's desire to please its owner shows up as clinical improvement. We talked about it for an hour. 17 audience questions. And yes, her cat made a cameo. Full replay here: https://lnkd.in/gC8-Web7 #AnimalHealth #VeterinaryResearch #ClinicalResearch

Three numbers that veterinary clinical trial designers should reconcile before writing their next protocol: 39.7% — the proportion of owners who reported improvement in placebo-treated dogs with osteoarthritis (Conzemius & Evans, 2012, JAVMA). 79.3% — the proportion of those same dogs that showed zero change on force platform analysis. That's a 40-point gap between what caregivers perceive and what objective measurement confirms. In veterinary medicine, the "placebo effect" isn't what most people think it is. Animals don't experience belief-driven responses. What inflates placebo group outcomes is a stack of five measurable phenomena, from caregiver bias to regression to the mean. Each one requires a different design strategy to control. When these mechanisms aren't addressed individually, the result is predictable: studies that can't demonstrate treatment superiority. Not because the drug failed. Because the control group looked better than it was. At our next Animal Health Insights Town Hall, Dr. Marie-Paul Lachaud, DVM (One Health Pharma) and Prelude CEO Tommy Buchanan Jackson break down the published placebo response data by therapeutic area and the protocol-level strategies that separate real treatment effects from caregiver perception. Register for the Town Hall here: https://lnkd.in/drRrPSNB #AnimalHealth #ClinicalTrials #VeterinaryResearch #StudyDesign

At one of the world's largest animal health companies, the human pharma researchers and the animal health researchers had never met. Same building. Same company. Different sides of the aisle. Randolph Legg, former US President of Boehringer Ingelheim Animal Health, told us what happened when he finally introduced them. Link here: https://lnkd.in/gaSbvaka #AnimalHealth #RealWorldEvidence #ClinicalTrials #VeterinaryMedicine #AnimalHealthInsights